2014
DOI: 10.1093/europace/euu085
|View full text |Cite
|
Sign up to set email alerts
|

Computational cardiac electrophysiology is moving towards translation medicine

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2015
2015
2018
2018

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 10 publications
0
2
0
Order By: Relevance
“…Advances in computational cardiac electrophysiology were recently illustrated in two dedicated special issues of Europace 2014 . 4,5 Furthermore, new initiatives such as the Comprehensive in vitro Proarrhythmia Assay (CiPA) launched by the United States Food and Drug Administration (FDA) recognize the potential of human-based in silico and in vitro approaches as a new paradigm for drug safety assessment. 6 …”
Section: Motivationmentioning
confidence: 99%
“…Advances in computational cardiac electrophysiology were recently illustrated in two dedicated special issues of Europace 2014 . 4,5 Furthermore, new initiatives such as the Comprehensive in vitro Proarrhythmia Assay (CiPA) launched by the United States Food and Drug Administration (FDA) recognize the potential of human-based in silico and in vitro approaches as a new paradigm for drug safety assessment. 6 …”
Section: Motivationmentioning
confidence: 99%
“…In order to overcome the current clinical lackings and become an effective supportive tool, computational hemodynamics has recently started to be adopted from a translational medicine perspective [44,45]. In particular, lumped-parameter approaches have been recently exploited to simulate AF conditions and evaluate the global hemodynamic response [42,43,3].…”
Section: Introductionmentioning
confidence: 99%